XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaboration Arrangements (Details) (USD $)
3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended
Mar. 31, 2012
GSK
Mar. 31, 2011
GSK
Mar. 31, 2012
VIBATIV
Maximum
Mar. 31, 2012
Long-acting beta agonist (LABA) collaboration
GSK
product
Mar. 31, 2012
Long-acting beta agonist (LABA) collaboration
LAMA/LABA
GSK
Maximum
Mar. 31, 2012
Long-acting beta agonist (LABA) collaboration
LABA/RELOVAIR collaboration
GSK
Y
Mar. 31, 2011
Long-acting beta agonist (LABA) collaboration
LABA/RELOVAIR collaboration
GSK
Nov. 30, 2010
2004 Strategic alliance
Common stock
Glaxo Group Limited, an affiliate of GSK
Oct. 31, 2004
2004 Strategic alliance
Class A common stock
GlaxoSmithKline LLC, an affiliate of GSK
May 31, 2004
2004 Strategic alliance
Class A common stock
GlaxoSmithKline LLC, an affiliate of GSK
Mar. 31, 2012
2004 Strategic alliance
LAMA
GSK
Mar. 31, 2012
2004 Strategic alliance
MABA
GSK
product
Mar. 31, 2011
2004 Strategic alliance
MABA
GSK
Mar. 31, 2012
2004 Strategic alliance
MABA containing '081
GSK
Mar. 31, 2012
2004 Strategic alliance
MABA containing '081 - single-agent
GSK
Mar. 31, 2012
2004 Strategic alliance
MABA containing '081 - single-agent
GSK
Maximum
Mar. 31, 2012
2004 Strategic alliance
MABA containing '081 - single-agent
GSK
Minimum
Mar. 31, 2012
2004 Strategic alliance
MABA containing '081 - combination product
GSK
Mar. 31, 2012
2004 Strategic alliance
MABA containing additional MABA
GSK
product
Mar. 31, 2012
2004 Strategic alliance
MABA containing additional MABA
GSK
Maximum
Mar. 31, 2012
2004 Strategic alliance
MABA containing additional MABA - single-agent
GSK
Mar. 31, 2012
2004 Strategic alliance
MABA containing additional MABA - single-agent
GSK
Maximum
Mar. 31, 2012
2004 Strategic alliance
MABA containing additional MABA - single-agent
GSK
Minimum
Mar. 31, 2012
2004 Strategic alliance
MABA containing additional MABA - combination product
GSK
Mar. 31, 2011
2004 Strategic alliance
Non-license specific
GSK
Mar. 31, 2012
2004 Strategic alliance
Non-license specific
GSK
Feb. 29, 2012
Governance agreement
Common stock
GSK
Nov. 30, 2011
Governance agreement
Common stock
GSK
Aug. 31, 2011
Governance agreement
Common stock
GSK
May 31, 2011
Governance agreement
Common stock
GSK
Feb. 28, 2011
Governance agreement
Common stock
GSK
Jul. 31, 2011
Governance agreement
Class A common stock
GSK
Mar. 31, 2012
License, development and commercialization agreement
VIBATIV
Astellas
Y
Mar. 31, 2011
License, development and commercialization agreement
VIBATIV
Astellas
Information related to collaboration arrangements                                                                    
Maximum obligation for milestone payments to GSK       $ 220,000,000                                                            
Number of combination products       2                                                            
If global regulatory authorities accept the applications for RELOVAIR, which the Company anticipates will be filed by GSK beginning in mid-2012, a portion of these potential milestone payments could be payable to GSK within the next two years.           2                                                        
Royalty rate for first level of annual global net sales (as a percent)           15.00%                   20.00% 10.00%         15.00% 10.00%                      
Royalty rate for combination products as a percentage of the rate applied to single products                                   70.00%           50.00%                    
Royalty rate for sales above first level of annual global net sales (as a percent)           5.00%                 7.50%           10.00%                          
Percentage of royalties receivable         10.00%                                                          
Percentage of royalties payable to Astellas                                                                 2.00%  
Amount of purchase agreements for pharmaceutical ingredient and raw materials     6,200,000                                                              
Amount of purchase agreements for for finished goods inventory     4,200,000                                                              
Liability recorded due to termination agreement                                                                 150,000  
Annual global sales level used to determine royalty rate           3,000,000,000                 3,500,000,000           3,500,000,000                          
Number of products which Company is obligated to use diligent efforts to discover after license of a program                                     6                              
Number of combination products to be developed and commercialized                       1                                            
Potential upfront license and milestone payments that Company could receive                             125,000,000                                      
Potential upfront license and milestone payments that Company could receive in respect of combination medicines                           250,000,000                                        
Milestone payments receivable                                       129,000,000                            
Entity's common stock information                                                                    
Common Stock Shares Purchased               5,750,000 433,757 6,387,096                                                
Aggregate Amounts               129,400,000 6,900,000 108,900,000                                                
Issuance of common stock for cash in private placement to a related party (in shares)                                                     88,468 58,411 102,466 261,299 152,278      
Issuance of common stock for cash in private placement to a related party                                                     1,603,000 1,298,000 2,020,000 6,689,000 3,609,000      
Shares of Class A common stock converted into common stock                                                               9,401,499    
Number of shares of Class A stock convertible into one share of common stock                                                               1    
Number of shares of common stock into which one share of Class A stock can be converted                                                               1    
GSK Upfront License Fees, Milestone Payments and Revenue                                                                    
Upfront License Fees 41,000,000         10,000,000         5,000,000 6,000,000                           20,000,000                
Milestone Payments 69,000,000         50,000,000         3,000,000 16,000,000                                            
Total 110,000,000         60,000,000         8,000,000 22,000,000                           20,000,000                
Term of royalty payment (in years)                                                                 10  
License, Development and Commercialization Agreement with Astellas                                                                    
Upfront license, milestone and other fees received                                                                 191,000,000  
Net revenue recognized under the collaboration                                                                    
Recognition of deferred revenue 1,430,000 2,456,000       907,000 1,270,000         523,000 502,000                       684,000                  
Recognition of deferred revenue                                                                 125,819,000 3,244,000
Royalties from net sales of VIBATIV                                                                   631,000
VIBATIV-labeled product sales allowance                                                                 150,000  
Total net revenue                                                                 $ 125,669,000 $ 3,875,000